Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atezolizumab At Last: Roche Makes Its Immuno-Oncology Debut

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's accelerated approval of Tecentriq, the first PD-L1 inhibitor, in bladder cancer is a major milestone for checkpoint inhibitors and for a disease with high unmet need; lung filing still under review.

Advertisement

Related Content

Roche's Tecentriq Gets The Double At The EU CHMP
Avastin Redux? Genentech’s Tecentriq Trial Failure Puts Bladder Cancer Claim At Risk
Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel